AIMT Aimmune Therapeutics Inc.

20.21
-0.19  -1%
Previous Close 20.4
Open 20.4
Price To Book 4.22
Market Cap 1256782981
Shares 62,186,194
Volume 645,258
Short Ratio
Av. Daily Volume 617,592

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - March 25, 2019.
AR101 ARTEMIS
Peanut Allergy
Phase 3 data released November 8, 2018 noted no serious adverse events
AR101 RAMSES
Peanut Allergy
BLA filing announced December 21, 2018. BLA filing acceptance expected by end of March 2019 (delay due to govt shutdown).
AR101
Peanut Allergy
Phase 2 trial to be initiated mid-2019.
AR 201
Egg Allergy
Phase 2 trial to be initiated 2H 2019.
AR 301
Walnut Allergy
Phase 2 trial initiation announced October 15, 2018.
AR101 with adjunctive dupilumab
Peanut Allergy
Phase 3 initiation announced December 19, 2018.
AR101 POSEIDON
Peanut Allergy

Latest News

  1. Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference
  2. Peninsula biotech lines up chance to crack the peanut allergy nut
  3. European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
  4. 4 Blockbuster Drug Launches to Watch in 2019
  5. Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
  6. NASH, Allergies and Beauty Stocks: Invest or Not?
  7. U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
  8. Edited Transcript of AIMT earnings conference call or presentation 28-Feb-19 10:00pm GMT
  9. Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Today's Competitive Landscape
  10. Aimmune Therapeutics to Participate in Three Investor Conferences in March
  11. Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights
  12. Aimmune Therapeutics Presents New AR101 Data at AAAAI, Including Demonstrated Reduction in Accidental Exposures to Peanut Requiring Treatment
  13. Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
  14. Trading Notes for Select Stocks
  15. Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting
  16. 6 Biotech Stocks to Watch Now
  17. 3 Top Biotech Stocks to Buy Right Now
  18. 3 Biotech Stocks That Could Be Slapped by the U.S. Government Shutdown
  19. 3 Potential New Drugs Held Up by the Shutdown
  20. Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial Officer